Nicholas A Hoerter1, Sarah E Shannahan2, Jorge Suarez1, Suzanne K Lewis1, Peter H R Green1, Daniel A Leffler2, Benjamin Lebwohl3. 1. The Celiac Disease Center at Columbia University, 180 Fort Washington Avenue, Suite 936, New York, NY, 10032, USA. 2. Celiac Disease Center, Beth Israel Deaconess Medical Center, East Campus, Dana 601, 330 Brookline Avenue, Boston, MA, 02215, USA. 3. The Celiac Disease Center at Columbia University, 180 Fort Washington Avenue, Suite 936, New York, NY, 10032, USA. bl114@cumc.columbia.edu.
Abstract
BACKGROUND: Serologic testing for celiac disease includes tissue transglutaminase and endomysial antibodies. In addition to these tools, assays for deamidated gliadin peptide antibodies have been shown to have sensitivity and specificity that are comparable to tissue transglutaminase testing, and are increasingly being used for celiac disease testing. AIMS: The goal of this study is to evaluate the utility of deamidated gliadin peptide (DGP) testing in the setting of a negative tissue transglutaminase (TTG) IgA test. METHODS: We reviewed the records of all patients seen at two U.S. celiac disease referral centers and identified those who had an elevated DGP IgA and/or IgG in the setting of a negative TTG IgA. Of these patients, those who underwent duodenal biopsy while on a gluten-containing diet were included. Patients with prior biopsy-proven celiac disease or prior TTG IgA positivity were excluded. The results of the biopsy were used as the gold standard for celiac disease diagnosis, and patients with villous atrophy (Marsh class 3) on duodenal biopsy were considered to have celiac disease. RESULTS: Between the two institutions, 84 patients were identified with negative TTG IgA and positive DGP IgA or IgG who also had duodenal biopsies performed while maintaining a gluten-containing diet. Of these patients, 13 patients (15.5%; 95% CI 8.5-25.0%) were found to have celiac disease on duodenal biopsy. CONCLUSIONS: DGP antibody testing can identify cases of celiac disease in TTG-negative individuals, although the low positive predictive value suggests that the yield may be low.
BACKGROUND: Serologic testing for celiac disease includes tissue transglutaminase and endomysial antibodies. In addition to these tools, assays for deamidated gliadin peptide antibodies have been shown to have sensitivity and specificity that are comparable to tissue transglutaminase testing, and are increasingly being used for celiac disease testing. AIMS: The goal of this study is to evaluate the utility of deamidated gliadin peptide (DGP) testing in the setting of a negative tissue transglutaminase (TTG) IgA test. METHODS: We reviewed the records of all patients seen at two U.S. celiac disease referral centers and identified those who had an elevated DGP IgA and/or IgG in the setting of a negative TTG IgA. Of these patients, those who underwent duodenal biopsy while on a gluten-containing diet were included. Patients with prior biopsy-proven celiac disease or prior TTG IgA positivity were excluded. The results of the biopsy were used as the gold standard for celiac disease diagnosis, and patients with villous atrophy (Marsh class 3) on duodenal biopsy were considered to have celiac disease. RESULTS: Between the two institutions, 84 patients were identified with negative TTG IgA and positive DGP IgA or IgG who also had duodenal biopsies performed while maintaining a gluten-containing diet. Of these patients, 13 patients (15.5%; 95% CI 8.5-25.0%) were found to have celiac disease on duodenal biopsy. CONCLUSIONS:DGP antibody testing can identify cases of celiac disease in TTG-negative individuals, although the low positive predictive value suggests that the yield may be low.
Authors: Pieter Vermeersch; Thomas Richter; Almuthe C Hauer; Martin Stern; Holm H Uhlig; Klaus-Peter Zimmer; Martin W Laass; Ilse Hoffman; Martin Hiele; Thomas Mothes; Xavier Bossuyt Journal: Clin Biochem Date: 2010-10-12 Impact factor: 3.281
Authors: Emilia Sugai; María L Moreno; Hui J Hwang; Ana Cabanne; Adriana Crivelli; Fabio Nachman; Horacio Vázquez; Sonia Niveloni; Julio Argonz; Roberto Mazure; Graciela La Motta; María E Caniggia; Edgardo Smecuol; Néstor Chopita; Juan C Gómez; Eduardo Mauriño; Julio C Bai Journal: World J Gastroenterol Date: 2010-07-07 Impact factor: 5.742
Authors: Kassem Barada; Robert H Habib; Ahmad Malli; Jana G Hashash; Houssam Halawi; Karim Maasri; Ayman Tawil; Fadi Mourad; Ala I Sharara; Assaad Soweid; Ismail Sukkarieh; Zaher Chakhachiro; Mark Jabbour; Alessio Fasano; Debbie Santora; Carolina Arguelles; Joseph A Murray; Peter H Green Journal: Endoscopy Date: 2014-01-29 Impact factor: 10.093
Authors: Afzal J Naiyer; Lincoln Hernandez; Edward J Ciaccio; Konstantinos Papadakis; John S Manavalan; Govind Bhagat; Peter H R Green Journal: J Clin Gastroenterol Date: 2009-03 Impact factor: 3.062
Authors: Ning Wang; Lennart Truedsson; Kerstin Elvin; Bengt A Andersson; Johan Rönnelid; Lucia Mincheva-Nilsson; Annica Lindkvist; Jonas F Ludvigsson; Lennart Hammarström; Charlotte Dahle Journal: PLoS One Date: 2014-04-07 Impact factor: 3.240
Authors: Govind K Makharia; Prashant Singh; Carlo Catassi; David S Sanders; Daniel Leffler; Raja Affendi Raja Ali; Julio C Bai Journal: Nat Rev Gastroenterol Hepatol Date: 2022-01-03 Impact factor: 46.802